Idasanutlin
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera
Conditions
Polycythemia Vera
Trial Timeline
Feb 21, 2018 → Mar 3, 2020
NCT ID
NCT03287245About Idasanutlin
Idasanutlin is a phase 2 stage product being developed by Roche for Polycythemia Vera. The current trial status is terminated. This product is registered under clinical trial identifier NCT03287245. Target conditions include Polycythemia Vera.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03287245 | Phase 2 | Terminated |
| NCT03362723 | Phase 1 | Completed |
Competing Products
20 competing products in Polycythemia Vera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 77 |
| ruxolitinib tablets | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| Ruxolitinib | Novartis | Phase 3 | 77 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 52 |
| Hydroxyurea | Novartis | Approved | 85 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 77 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 52 |
| PEGASYS + Aspirin | Roche | Phase 2 | 52 |
| RG7388 + Pegasys | Roche | Phase 1 | 33 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 77 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 51 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 76 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 76 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 84 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 51 |
| P1101 (Ropeginterferon alfa-2b) | PharmaEssentia | Phase 3 | 76 |